NCT00214565终止3 期
A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 1,450
- 试验地点
- 73
- 主要终点
- Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)
研究概览
简要总结
This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of a written informed consent
- •Men or women who are ³18 years of age
- •Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
- •Diagnosed with type 2 diabetes
- •Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
排除标准
- •Type 1 diabetes
- •New York Heart Association heart failure Class III or IV
- •Treatment with chronic insulin
- •History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
- •History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
- •Creatinine levels above twice the normal range
- •Creatine kinase above 3 times the upper limit of normal
- •Received any investigational product in other clinical studies within 12 weeks
- •Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
结局指标
主要结局
Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)
次要结局
- The change in fasting plasma glucose (FPG), insulin, proinsulin and C-peptide
- Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model
- Lipid parameters
- FPG, homeostasis assessment model, insulin, proinsulin, C-peptide
- Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values
- Pharmacokinetics of tesaglitazar
- Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination
- Assess the effects on patient-reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36)
- Validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) (US only).
研究者
研究点 (73)
Loading locations...
相似试验
招募中
2 期
A Study of the Efficacy and Safety of WXSH0102 in Treating VCC PatientsVaginitisNCT06771063Cisen Pharmaceutical CO., LTD.108
终止
2 期
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)Diabetes Mellitus, Type 2NCT00229684AstraZeneca100
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-203Acute GastritisChronic GastritisNCT04066530Addpharma Inc.475
进行中（未招募）
不适用
Olpadronate intra venous in chronic low back painon-specific Chronic Low Back Pain persisting for at least 3 monthsMedDRA version: 18.1Level: LLTClassification code 10008837Term: Chronic back painSystem Organ Class: 100000004859EUCTR2015-004269-96-NLGador S.A.
已完成
2 期
A 24 weeks multicentre, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy, safety and tolerability of intravenous IG-8801 20 mg and 40 mg in subjects with chronic low back paidegenerative afwijkingen van de lumbale wervelkolom leidend tot axiale aspecifieke en chronische lage rugpijnaspecific low back painchronic low back painNL-OMON46893Gador S.A.58